Sitagliptin

Limits on what this shows

• Key negative/null findings: None identified; no study found reported sitagliptin impairing mitochondrial structure or function in any species.
• At-risk subgroups: Not applicable; direction found is protective, not depleting, and unconfirmed beyond cell culture.
• Counter-evidence on record: None found contradicting the direction; the main limitation is the complete absence of animal or human confirmation.

Regulatory status

No mitochondrial toxicity signal or benefit claim in FDA labeling.

Population evidence

Tier B, in vitro only: human SH-SY5Y neuronal cells exposed to sitagliptin showed increased PGC-1alpha/NRF1/TFAM expression and increased mitochondrial respiratory rate (Weng et al., IUBMB Life 2019;71(10):1515-1521). [6] A second in vitro study in hypoxia/reoxygenation-stressed cardiac microvascular endothelial cells reported sitagliptin "improved H/R-induced mitochondrial dysfunction by increasing intracellular MMP and ATP." [7] No animal or human clinical mitochondrial-function data were identified for sitagliptin.

Mechanism

Proposed activation of PGC-1alpha-driven mitochondrial biogenesis signaling; not confirmed in vivo or in humans.

Counter-evidence held on record

In vitro findings do not establish a clinical benefit. This is not a basis for "mitochondrial support" marketing claims, and shares its underlying sources with the ATP production entry below (see Overlap map).

Limits on what this shows

• Key negative/null findings: None identified; no study found reported sitagliptin worsening oxidative stress markers in any model.
• At-risk subgroups: Cannot be defined; findings are limited to rodent injury/disease models, not healthy or human subjects.
• Counter-evidence on record: No human oxidative-stress-biomarker study in sitagliptin-treated patients was located despite repeated searches; this represents a genuine gap in translation to humans, not a null finding.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Tier B, animal only, all with sitagliptin directly administered: streptozotocin-diabetic nephropathy rats, reduced oxidative stress via the miR-200a/Keap-1/Nrf2 pathway. [8] Two-kidney-one-clip hypertensive rats, reduced oxidative stress and inflammation in heart and kidney. [9] Rat hepatic ischemia-reperfusion model, reduced oxidative, nitrative, and halogenative stress markers. [10] Diabetic mouse liver-inflammation model, sitagliptin acted as a "ROS scavenger" and inhibited NF-κB signaling. [11] DSS-induced colitis mouse model, oxidative stress modulated alongside inflammatory markers (full text not confirmable during this review; see access note). [12]

Mechanism

Proposed direct ROS-scavenging chemistry and Nrf2/antioxidant-pathway activation attributed to the sitagliptin molecule itself, independent of glucose lowering.

Counter-evidence held on record

A consistent preclinical signal across independent rodent injury models does not equal a human antioxidant benefit. Should not be used to justify reducing dietary or supplemental antioxidant intake.

Limits on what this shows

• Key negative/null findings: The null result (no incremental effect of adding sitagliptin) is itself the primary finding. [4]
• At-risk subgroups: Patients on combination sitagliptin/metformin products (Janumet) should be monitored per metformin's established profile; this is a metformin consideration, not a sitagliptin-specific one.
• Counter-evidence on record: A Tier B animal study (dextran-sulfate-sodium colitis model) also measured serum iron in sitagliptin-treated animals, but its full text and abstract could not be opened after repeated attempts during this review (see access note); its directional result is not used here. [12]

Regulatory status

No iron-related warning or interaction in FDA labeling.

Population evidence

Tier A: comparative cohort, n=118 adults with type 2 diabetes followed one year (Rev Assoc Med Bras; 59 on metformin monotherapy, 59 on metformin plus a gliptin, of whom 24 were on sitagliptin/metformin and 35 on vildagliptin/metformin). Ferritin declined in both groups, with no statistically significant difference in the magnitude of decline between metformin-alone and metformin-plus-gliptin arms. [4]

Mechanism

None specific to sitagliptin identified in the pharmacokinetic and mechanism screen (no absorption interference, no documented hepcidin or inflammatory-pathway effect). The decline pattern is most consistent with metformin's own established B12/iron-adjacent pharmacology or with diabetes duration, not sitagliptin.

Counter-evidence held on record

This is not evidence that sitagliptin depletes iron; it is direct evidence against an independent sitagliptin effect. It is graded (not left ungraded) because iron is a mandatory Step 3 category and real, drug-specific Tier A data exist. Shares its underlying source with the Vitamin B12 entry in Fails verification (see Overlap map).

Limits on what this shows

• Why no grade: Both conditions for ungraded were met: (1) targeted PubMed searches for "sitagliptin copper" and "sitagliptin" AND "ceruloplasmin" returned only unrelated synthetic-chemistry papers on sitagliptin-metal coordination complexes for spectroscopy/electrochemistry, not physiological copper status, so no Tier B or Tier C evidence exists; and (2) none of the consumer nutrient-depletion resources reviewed (US Pharmacist, Rupa Health, BodyBio) makes any copper claim for sitagliptin or DPP-4 inhibitors, so there is no circulating claim to rebut as white.

Tooling note

These searches completed successfully and returned results (not blocked); this reflects a genuine gap in the literature searched, not an access failure.

Limits on what this shows

• Key negative/null findings: The human RCT is itself the key null finding: no change in alpha or beta diversity over 12 weeks despite measurable changes in fecal bile acids and HbA1c. [3]
• At-risk subgroups: None identified.
• Counter-evidence on record: None contradicting; this category is unusually well supported by a genuine drug-specific randomized trial rather than mechanism reasoning alone.

Regulatory status

Not addressed in FDA labeling; no microbiome warning or claim.

Population evidence

Tier A: randomized, placebo-controlled trial, n=51 adults with type 2 diabetes (liraglutide, sitagliptin 100 mg, or placebo, 12 weeks), fecal 16S rRNA sequencing: "neither liraglutide nor sitagliptin affected either alpha or beta diversity." [3] Tier B: streptozotocin-induced diabetic rat model in which sitagliptin ameliorated microbial dysbiosis and improved gut barrier integrity. [5]

Mechanism

No mechanism needed for the null human result. Proposed anti-inflammatory/barrier-protective mechanism for the animal finding is not confirmed in humans.

Counter-evidence held on record

Do not present this as "sitagliptin protects the gut microbiome" to consumers. The human data show no measured change, not improvement; the protective signal exists only in a diabetic-rat model and is not established in people.

Limits on what this shows

• Key negative/null findings: None identified.
• At-risk subgroups: Not applicable; reverse-direction, preclinical-only finding.
• Counter-evidence on record: None found contradicting; no animal or human ATP data exist to confirm or refute translation.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Tier B, in vitro only: sitagliptin increased ATP production alongside mitochondrial biogenesis markers in human SH-SY5Y neuronal cells. [6] Sitagliptin increased intracellular ATP and mitochondrial membrane potential in hypoxia/reoxygenation-stressed cardiac microvascular endothelial cells. [7]

Mechanism

Proposed via PGC-1alpha-driven mitochondrial biogenesis and stress-protection signaling; not confirmed in animals or humans.

Counter-evidence held on record

Not a basis for energy or fatigue marketing claims. This entry and the mitochondrial-burden entry rest on the same two underlying papers (see Overlap map) and should not be read as two independent confirmations.

Limits on what this shows

• Key negative/null findings: In the case report itself, hemoglobin did not fall meaningfully despite the hemolysis markers; this was a mild, self-limited reaction. [13]
• At-risk subgroups: Cannot be defined from a single case; no risk factor was identified or excluded.
• Counter-evidence on record: None found beyond the class-level review's own stated uncertainty; no population-level hemoglobin or hematocrit signal for sitagliptin specifically was located.

Regulatory status

Hemolysis or anemia is not listed as an adverse reaction in FDA labeling.

Population evidence

Tier B case report (Indian J Pharmacol 2010): 62-year-old male with type 2 diabetes; on sitagliptin re-challenge, indirect bilirubin rose to 1.9 mg/dL, reticulocyte count rose to 4.32%, LDH rose to 789 U/L, while hemoglobin remained stable at 13.5 g%; all values normalized within 10 days of discontinuation. [13] Tier C class-level narrative review (Med Sci [Basel] 2026) covering incretin-based therapies broadly (GLP-1 receptor agonists and DPP-4 inhibitors together, not stratified to sitagliptin): "current evidence is insufficient to establish a direct causal relationship or a class-wide adverse effect" on hematologic parameters. [14]

Mechanism

Not established; the case report proposes no specific biochemical mechanism and does not document G6PD deficiency or another known hemolysis risk factor.

Counter-evidence held on record

This does not establish a population-level anemia or hemolysis risk. It documents a rare, reversible, idiosyncratic reaction worth clinical awareness (unexplained jaundice, dark urine, fatigue on sitagliptin), not a reason for routine hematologic screening.